Mary Bird Perkins Cancer Center’s Post

Louisiana has a higher incidence of cancer and a lower rate of survival than most states. That's unacceptable. We need to come together improve prevention, diagnosis and treatment. We CAN make an impact! Check out what Joe W. Ramos, PhD shared with Biz Orleans on how a National Cancer Institute Designated Cancer Center will finally change the trajectory of cancer in Louisiana. Cancer can be a diagnosis that people LIVE with, not die from. We can do it in our lifetime. Get screened. https://lnkd.in/gtzM7k8p

🔬In the dynamic realm of research, the partnership between BIG and EORTC - European Organisation for Research and Treatment of Cancer stands as a testament to the power of collaboration. United by a common mission, their synergy has consistently brought vital conversations to the forefront, making strides in awareness about breast cancer research and treatment. Over the past 4 years, their joint webinars have been a beacon of knowledge: 📌 2019: “Breast cancer: What do I need to know?” 📌 2020: “De-escalation of breast cancer treatments” 📌 2021: “I have metastatic breast cancer: what is my future?” 📌 2022: “The unmet needs of older patients with breast cancer”. Each session, rich in insights and expertise, contributes to shaping research trajectories and enlightening all those who attend. This year, we are joining forces again to invite you to a new edition of the webinar which will focus on "Overcoming the Challenges of Funding Academic Breast Cancer Research." 👉🔗 Register now: https://lnkd.in/evJ-yQ4j #BIGEORTC23 #FundingAcademicResearch #PinkOctober23 #BIGmissing #Imissyou #BIGagainstbc #ResearchSavesLives #EU4Health European Health and Digital Executive Agency (HaDEA)

🔬 Delighted to announce our recent publication in Frontiers in Oncology. A massive shoutout to the stellar team – Otto Visser, Beata Kościańska, Florentino Caetano dos Santos, Francesco Cuccaro, Gonçalo Forjaz, Mohsen Mousavi, Urszula Sulkowska, Carmen Martos Jiménez, and Francesco Giusti! 🌐 Our work on the 2022 revised European recommendations for cancer diagnosis coding is now live, making waves in the field and impacting daily work of Cancer Registries in Europe. These updated guidelines, effective from January 1, 2023, keep pace with evolving diagnostic techniques, ensuring top-notch quality in cancer data. Let's keep the momentum going in advancing cancer research! 🚀🧬 #CancerCoding #ResearchMilestones #InnovationInOncology #CancerRegistry https://lnkd.in/dwRt5n_n

The Association of American Cancer Institutes (AACI) represents more than 100 premier academic and freestanding cancer centers in North America. AACI is accelerating progress against cancer by enhancing the impact of academic cancer centers and promoting cancer health equity. The National Cancer Plan provides structure and strategies that help guide AACI’s work on behalf of the cancer centers. Read AACI's Strategic Impact: Promoting Engagement in Cancer Research, Equity, and Care to learn more about AACI's commitment to the National Cancer Plan. https://lnkd.in/ebaXzuq9 via National Cancer Institute (NCI). #NationalCancerPlan #CancerResearch #HealthEquity

To reduce the cancer mortality rate and transform the meaning of a cancer diagnosis, the #NationalCancerPlan lays out eight goals describing the essential aspects of progress. Research is critical to achieving the plan’s goals, but success will rely on everyone playing their part. Through its programs, initiatives, and events, AACI is working to engage every person, eliminate inequities, optimize the oncology workforce, and maximize data utility. AACI collaborates with over 100 academic and freestanding cancer centers in North America to enhance their impact in cancer prevention, detection, treatment, and care. Learn more about AACI's Commitment to the National Cancer Plan via National Cancer Institute (NCI): https://lnkd.in/ebaXzuq9 #Every1HasARole #CancerMoonShot

Cancer research has always been a complex field, requiring accurate, timely, and comprehensive data to drive effective treatments and cures. The traditional challenges of fragmented data sources and complex datasets have often hindered progress. At Acoer, we have been hard at work to solve this problem and improve cancer research for everyone. Therefore, last week we introduced our Cancer Trials Explorer, a tool designed to enhance the way patients, researchers, and healthcare professionals access and analyze cancer clinical trial data. In this blog post, we dig deeper into all aspects of Cancer Trials Explorer, as well as current challenges in cancer research. Read more here: https://lnkd.in/eTPhZ5cx #CancerResearch #ClinicalTrials #ClinicalResearch #MedicalInnovation #BlockchainHealthcare #CancerAwareness

More patients these days are taking part in cancer research, a new study published in the Journal of Clinical Oncology finds. At least one in five people with cancer (22%) participate in some form of clinical research, when all types of cancer studies are considered, researchers found. Moreover, enrollment in cancer treatment trials was 7%, more than double previous participation estimates of 2% to 3% of patients. Participation in treatment trials was more than five-fold higher at National Cancer Institute-designated cancer centers than at community hospitals, 22% versus 4%. "We know that most patients with cancer will participate in a clinical trial if given the chance, and the level of enrollment we see at NCI-designated cancer centers shows what participation can be when patients are offered trials," said senior researcher Mark Fleury. #CancerResearch https://ow.ly/Nzy350RbS1l

Talking about those impacted by cancer on #WorldCancerDay is important, but taking action is how we really make a difference the lives of patients and their loved ones. Discover how TFS is contributing to the Union for International Cancer Control (UICC)'s efforts to #CloseTheCareGap by reading our recent blog post and join us in making a difference today, on World Cancer Day, and every day. https://lnkd.in/eF8twxCh

“Mutations to KRAS are linked to a third of all human cancers and it was considered undruggable. The achievement of being able to target just the cells with the mutation is an incredible legacy of science’s advances.” The FDA has approved 11 new immune checkpoint inhibitors since 2011, which help the immune system go after cancer cells more effectively. Precision oncology has great potential in increasing efficacy and reducing toxicity. What implications does this hold for the future of cancer care, both during and after treatment? Join us at the #FutureofCancerCare Summit, in collaboration with CancerX Moonshot, on November 8th-9th 2023 in Tampa, FL to hear about how cancer care is advancing in alignment with new therapies. #cancerresearch #precisiononcology #immunotherapy https://lnkd.in/eEK-YbTX

Cancer #clinicaltrials tend to face more complex challenges compared to non-oncology trials. This is due to the many types of cancers to treat, the different signaling pathways (at least 12 of them) and the difficulties associated with recruiting cancer patients. Read this article to explore how we can rethink the complex process for cancer trials. https://bit.ly/3Ki5Ut2